REALITY: Mortality Not Improved With Addition of Raltegravir to First-line ART in Severely Immunosuppressed Adults and Children in Sub-Saharan Africa
Conference Capsule - Despite lack of impact on all-cause mortality, raltegravir-intensified ART associated with much faster reduction in HIV-1 RNA levels and greater increase in CD4+ cell counts at Week 48. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 29, 2016 Category: Infectious Diseases Source Type: research
ONCEMRK: Raltegravir 1200 mg QD Noninferior to Raltegravir 400 mg BID at Week 48 When Paired With TDF/FTC in Treatment-Naive Patients
Conference Capsule - Similar CD4+ cell count increases, rates of virologic failure, and safety outcomes observed for each regimen. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 26, 2016 Category: Infectious Diseases Source Type: research
Switch to Once-Daily Dolutegravir Plus Rilpivirine Safe and Effective in Virologically Suppressed HIV-Infected Patients With Multiple Previous ART Failures
Conference Capsule - Switch to daily DTG plus RPV associated with improved liver function tests, improved lipid profile, and stable kidney function. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 26, 2016 Category: Infectious Diseases Source Type: research
PADDLE: In Exploratory Trial, Dolutegravir Plus Lamivudine Dual Therapy Effective for Treatment-Naive Patients With HIV Through Week 48
Conference Capsule - In this pilot study, 90% of patients maintained virologic suppression through Week 48; 1 patient who had baseline HIV-1 RNA > 100,000 copies/mL experienced protocol-defined virologic failure at Week 36, and 1 patient was a victim of suicide deemed unrelated to study drugs. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 25, 2016 Category: Infectious Diseases Source Type: research
ARIA: Dolutegravir/Abacavir/Lamivudine Superior to Atazanavir/Ritonavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine in Treatment-Naive Women at Week 48
Conference Capsule - Superiority in ITT analysis driven by fewer discontinuations due to adverse events and virologic nonresponse; no treatment-emergent resistance observed in dolutegravir/abacavir/lamivudine arm (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 25, 2016 Category: Infectious Diseases Source Type: research
REALITY: Enhanced Prophylaxis for Opportunistic Infections at ART Initiation in Severely Immunocompromised Individuals Associated With Reduced Early Mortality
Conference Capsule - Enhanced prophylaxis also associated with improvements in severe disease or death, new TB, cryptococcal or candida infection, and hospitalization in study from sub-Saharan Africa. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 24, 2016 Category: Infectious Diseases Source Type: research
PROMISE 1077HS: Continued ART Safe, Provides Clinical Benefits in Postpartum Women With High CD4+ Cell Counts
Conference Capsule - Whereas rates of AIDS-defining events, serious outcomes, and death were low and not different for those who stopped vs continued ART, rates of WHO stage 2/3 events were cut in half for women who continued ART in the postpartum period. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 24, 2016 Category: Infectious Diseases Source Type: research
HIV Alert: Update on the Management of ART in HCV/HIV Coinfection
Slideset - In this downloadable slideset, Susanna Naggie, MD, MHS, and David L. Wyles, MD, review important considerations for managing ART in patients with HCV/HIV coinfection, including guideline recommendations, management of key drug –drug interactions, and potential liver toxicity with some antiretroviral agents. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 22, 2016 Category: Infectious Diseases Source Type: research
ATN 113: Daily Oral Tenofovir DF/Emtricitabine Well Tolerated in Adolescent MSM in US-Based PrEP Demonstration Project
Conference Capsule - Decreased adherence to PrEP over time aligned with increasing intervals between planned clinic visits. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 22, 2016 Category: Infectious Diseases Source Type: research
HPTN 069/ACTG A5305: Maraviroc-Containing PrEP Regimens Safe, Tolerable in Cohort of US Women
Conference Capsule - In first randomized interventional evaluation of HIV PrEP in US women, no safety or tolerability differences seen between maraviroc-containing PrEP vs TDF + FTC; no new HIV infections occurred over study course. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 21, 2016 Category: Infectious Diseases Source Type: research
Current Controversies in HIV Management
Video Module - Watch and listen as David A. Wohl, MD, leads a panel of experts in discussing their thoughts on some of the most pertinent current controversies related to the prevention and treatment of HIV infection. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 13, 2016 Category: Infectious Diseases Source Type: research
The Imperative for Women-Initiated HIV Prevention Technologies
Discussion - Professor Quarraisha Abdool Karim, PhD, introduces her take on one of the key challenges for women at risk of HIV infection and evolving strategies for prevention. At an upcoming symposium in Durban, Catherine Hankins, MD, PhD, FRCPC, CM, and a multidisciplinary panel of experts will continue this discussion by providing their perspectives on 3 global challenges to treatment and prevention of HIV in women. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 8, 2016 Category: Infectious Diseases Source Type: research
Challenging Cases in HIV Management
Video Module - Led by Daniel R. Kuritzkes, MD, a panel of experts discusses their personal approach to the management of challenging HIV case patients. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 8, 2016 Category: Infectious Diseases Source Type: research
Management of Advanced Liver Disease and Other Challenging HCV Cases
Video Module - Led by Paul Y. Kwo, MD, a panel of experts discusses their personal approach to the management of challenging HCV patients. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 27, 2016 Category: Infectious Diseases Source Type: research
HCV Retreatment and Resistance
Video Module - In this CME-certified video module, David L. Wyles, MD, moderates an expert panel discussion of best practices and evidence-based approaches to retreatment of patients with HCV who have failed previous therapy and the role of resistance testing for these patients. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 27, 2016 Category: Infectious Diseases Source Type: research
